Companies / Amerigo Scientific / CEA Antigen (recombinant)
Amerigo Scientific

CEA Antigen (recombinant) | Amerigo Scientific

CEA was first identified in human colon carcinoma tissue extracts and is known to play a critical role as a ligand in cancer dissemination. Elevated serum CEA is found in 17∼47% of colorectal cancer patients./

CEA was originally thought to be a specific marker for colon cancer but levels may also be raised in gastric, pancreatic, lung, breast and medullary thyroid carcinomas, as well as some non-neoplastic conditions such as inflammation, pancreatitis, ulcerative colitis, cirrhosis, COPD, Crohn's disease, hypothyroidism and in smokers. For this reason, it is not useful as a general cancer screening tool, but can be useful in evaluating the response to cancer treatment, to monitor metastasis of colorectal cancer to the liver and to indicate recurrence./

Elevated CEA levels should return to normal after successful surgical removal of the tumour and can be used in follow up, especially of colorectal cancers. CEA elevation is known to be affected by multiple factors and it varies inversely with tumor grade; well-differentiated tumours secrete more CEA.

Reviews


No reviews yet

ABOUT THE COMPANY

Amerigo Scientific is a distribution company focused on providing critical products and services to the biomedical and life science research communities. Although a new company, Amerigo Scientific's founder has had more than 20 years of rich experience in the biomedical and biochemical fields, and has established close contacts with key personnel in...
READ MORE